Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Intensive Case Management for Substance Use Disorders (RCT) (ICM)

13 novembre 2026 aggiornato da: Psychiatric Services Aargau AG

Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Canton of Aargau
      • Windisch, Canton of Aargau, Svizzera, 5210
        • Reclutamento
        • PDAG
        • Contatto:
        • Investigatore principale:
          • Johannes Senesi, Msc

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 64 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give informed consent
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental

receives ICM immediately

Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:

  1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients.
  2. Relationship continuity: Establishing an empathetic & constant presence, breaking down barriers, creating a trustful, stable relationship.
Comparatore attivo: Waiting List

Same as Experimental, only with 6-Month TAU-Waiting List before ICM

TAU will take place for 6 months before starting with ICM

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Inpatient Admissions (Health Service utilisation)
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
WHOQoL-BREF
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Quality of Life

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Social Functioning Questionnaire

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
ASSIST
Lasso di tempo: 6 Months (exploratory), 24 months (exploratory)

Substance use characteristics

6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Continuity of Care describes timeframes of the health services used outside the ward.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Lasso di tempo: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Retention describes the voluntary staying of patients in the ICM treatment

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Lasso di tempo: 6 Months (exploratory), 24 months (exploratory)

Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
Lasso di tempo: 6 Months (exploratory), 24 months (exploratory)

EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

6 Months (exploratory), 24 months (exploratory)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 luglio 2026

Completamento primario (Stimato)

1 luglio 2029

Completamento dello studio (Stimato)

1 luglio 2029

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • PDAG-ICM
  • HumRes68440 (Altro identificatore: Human Research Switzerland (HumRes))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi